TY - JOUR
T1 - Physical Agent-Based Treatments for Overactive Bladder
T2 - A Review
AU - Khasanah, Nurida
AU - Chin, Hung Yen
AU - Peng, Chih Wei
N1 - Funding Information:
The present study was generously funded by the Ministry of Science and Technology (110-2314-B-038-001, 110-2811-E-038-500-MY3, 110-2314-B-305-001, 109-2314-B-305-001, 109-2221-E-305-001-MY2, 109-2221-E-038-005-MY3, and 109-2314-B-038-132) and the University System of Taipei Joint Research Program (USTP-NTUT-TMU-111-03) of Taiwan. This work was also financially supported by the Higher Education Sprout Project (DP2-111-21121-01-N-03-04) of the Ministry of Education (MOE) in Taiwan.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/9
Y1 - 2022/9
N2 - Almost one-fifth of the people in the world experience a decrease in quality of life due to overactive bladder (OAB) syndrome. The main bothersome symptoms are urgency accompanied by urinary frequency and nocturia. This chronic, disabling condition is first managed by reducing fluid intake and pelvic floor muscle training, supplemented with antimuscarinic drugs, if necessary. However, refractory cases often still occur. In more severe cases, invasive surgical interventions can be considered; yet, the success rate is still inconsistent, and there is a high complication rate. This condition is frustrating for patients and challenging for the medical staff involved. Although its pathophysiology has not been fully elucidated, peripheral autonomic somatic and sensory afferent receptors are considered to be involved in this condition. Hence, currently, physical agent-based treatments such as neuromodulation have taken a significant place in the third-line therapy of OAB. The efficacy and safety profiles of electrical and magnetic stimulation continue to evolve. Physical-based agents provide an appealing option owing to their effectiveness and minimal side effects. In addition, more physical therapies using light and shock energy are currently being investigated. Thus, a comprehensive understanding of these modalities is an extremely important aspect to provide the most suitable modalities for patients.
AB - Almost one-fifth of the people in the world experience a decrease in quality of life due to overactive bladder (OAB) syndrome. The main bothersome symptoms are urgency accompanied by urinary frequency and nocturia. This chronic, disabling condition is first managed by reducing fluid intake and pelvic floor muscle training, supplemented with antimuscarinic drugs, if necessary. However, refractory cases often still occur. In more severe cases, invasive surgical interventions can be considered; yet, the success rate is still inconsistent, and there is a high complication rate. This condition is frustrating for patients and challenging for the medical staff involved. Although its pathophysiology has not been fully elucidated, peripheral autonomic somatic and sensory afferent receptors are considered to be involved in this condition. Hence, currently, physical agent-based treatments such as neuromodulation have taken a significant place in the third-line therapy of OAB. The efficacy and safety profiles of electrical and magnetic stimulation continue to evolve. Physical-based agents provide an appealing option owing to their effectiveness and minimal side effects. In addition, more physical therapies using light and shock energy are currently being investigated. Thus, a comprehensive understanding of these modalities is an extremely important aspect to provide the most suitable modalities for patients.
KW - electrical stimulation
KW - laser
KW - low-intensity shock energy
KW - magnetic stimulation
KW - neuromodulation
KW - overactive bladder
KW - physical-based agent
UR - http://www.scopus.com/inward/record.url?scp=85137766197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137766197&partnerID=8YFLogxK
U2 - 10.3390/jcm11175150
DO - 10.3390/jcm11175150
M3 - Review article
AN - SCOPUS:85137766197
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 17
M1 - 5150
ER -